Assumptions are made in new ADAP plan
Here are assumptions the Washington, DC-based ADAP Working Group used to make its funding projects for the coming year:
- Starting population (June 2002) — 84,378.
- Monthly growth — 635.
- Prophylaxis only — 10% (background rate for those on therapy is based on Florida. Of the remaining 90%, 3% mono, 5% dual, 73% triple, 15% quad and higher. Average — 3.12.
- Antiretroviral use based on Pennsylvania ADAP.
- Inflation rate for opportunistic infections and other drugs — 4.6% per year.
- Other costs (per person per month) — hyperlipidemia $5.48; insulin resistance $2.77; cardiovascular $5.32; gastrointestinal $11.58; antidiarrheals $1.44.
Assumptions based on new developments in treatment include:
- Fusion inhibitors. Fuzeon, approved this spring by the Food and Drug Administration, now is available. Estimates of Fuzeon utilization is based on availability reports and amount to about 20% of the available supply, which coincides with the ADAP patients in treatment. That calculates to about 2,500 slots by the end of FY 2003 and about 4,500 by the end of FY 2004. The cost is estimated at $24,500 per year for an entire course of the drug.
- Waiting list. Assumes that 1,200 patients will be on waiting lists in 2003.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content